IL10 and colitis: Administration of everolimus to IL-10-deficent mice, which develops spontaneous colitis, inhibits the proliferation of activated T cells, decreases the number of Th1 cells and the production of inflammatory cytokines by Th1 cells in the lamina propria, and ultimately ameliorates chronic colitis (59).